Slide 1: Puma Biotechnology Earnings Call Commercial Update
Puma Biotechnology Earnings Call Commercial Update August 4, 2022
Slide 2: Forward-Looking Safe-Harbor Statement
Forward-Looking Safe-Harbor Statement This presentation contains forward-looking statements, including statements regarding commercialization of NERLYNX® and the potential indications and development of our drug candidates. All forward-looking statements involve risks and uncertainties that could ca
Slide 3: PUMA's Pharmacy and Distributor Network
PUMA’s Pharmacy and Distributor Network Hub Services Specialty Pharmacy Network (SP) Acaria Health Accredo CVS ONCO 360 Patients Optum / Biologics Diplomat Sites of Care Specialty Distributor Network (SD) Academic Hospitals McKesson Community Hospitals ASD/Oncology Supply Physician Practices Cardina
Slide 4: ~$51 Million net NERLYNX revenue in Q2'22
~$51 Million net NERLYNX revenue in Q2’22 Quarterly Net Revenue (in $MM) 61.1 58.7 52.6 53.8 53.5 50.8 50.0 51.0 51.3 48.6 48.8 49.3 48.9 45.6 45.8 43.4 40.7 36.0 20.1 6.1 Copyright 2022 Puma Biotechnology 4
Slide 5: 3,200 Ex-factory bottles were sold in Q2'22
3,200 Ex-factory bottles were sold in Q2’22 Bottles Sold (SP + SD) by Quarter 5,538 4,936 4,935 4,799 4,791 4,696 4,452 4,035 3,728 3,611 3,517 3,585 3,454 3,247 3,354 3,200 2,947 2,680 2,137 675 Includes Commercial SP and SD Copyright 2022 Puma Biotechnology 5
Slide 6: ~65% of patients in Q2'22 started at a reduced dose
~65% of patients in Q2’22 started at a reduced dose* ** % of Patients starting at reduced dose 65.4% 61.5% 59.4% 54.9% 42.4% 37.7% 38.7% 32.8% 30.0% 31.0% 28.0% 19.0% 12.0% 11.0% 6.0% 7.0% 3.0% 4.0% 2.0% 2.0% *Reduced dose defined as fewer than 6 pills per day ** FDA approved dose-escalation label s
Slide 7: Rest of World Partnerships – Timelines
Rest of World Partnerships – Timelines Region Partner Regulatory Approvals Commercial Launches • 2019 – Ext. Adj. in Australia, Singapore • 2020 – Singapore Australia / SE Asia • 2020 – Ext. Adj. in Brunei, Malaysia, New Zealand • Q2 2021 – Malaysia • Q2 2022 – Ext. Adj. in the Philippines • Q3 / Q4
Slide 8: Puma Biotechnology
Puma Biotechnology Earnings Call Commercial Update August 4, 2022